Summary

Multiplex Assays Market – Scope of Report
TMR’s report on the global multiplex assayss market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global multiplex assayss market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global multiplex assayss market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the multiplex assayss market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global multiplex assayss market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global multiplex assayss market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global multiplex assayss market.

The report delves into the competitive landscape of the global multiplex assayss market. Key players operating in the global multiplex assayss market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global multiplex assayss market profiled in this report.

Key Questions Answered in Global multiplex assayss Market Report
• What is the sales/revenue generated by multiplex assayss across all regions during the forecast period?
• What are the opportunities in the global multiplex assayss market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Multiplex Assays Market – Research Objectives and Research Approach
The comprehensive report on the global multiplex assayss market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global multiplex assayss market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global multiplex assayss market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Multiplex Assays Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Multiplex Assays Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Multiplex Assays Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Instruments
6.3.2. Consumables
6.3.2.1. Reagents & Kits
6.3.2.2. Micropipettes & Microplates
6.3.2.3. Others
6.3.3. Software
6.4. Market Attractiveness, by Product
7. Global Multiplex Assays Market Analysis and Forecast, by Technology
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. Multiplex RT-PCR
7.3.2. Flow Cytometry
7.3.3. Luminescence
7.3.4. Fluorescence
7.3.5. Others
7.3.6. Market Attractiveness, by Technology
8. Global Multiplex Assays Market Analysis and Forecast, By Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Type, 2017–2031
8.3.1. Protein
8.3.1.1. Planar
8.3.1.2. Bead-based
8.3.2. Nucleic Acid
8.3.2.1. Planar
8.3.2.2. Bead-based
8.3.3. Cell
8.4. Market Attractiveness, By Type
9. Global Multiplex Assays Market Analysis and Forecast, by Application
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Research & Development
9.3.1.1. Drug Discovery & Research
9.3.1.2. Biomarker Research & Application
9.3.2. Diagnosis
9.3.2.1. Infectious Diseases
9.3.2.2. Autoimmune Diseases
9.3.2.3. Cancer
9.3.2.4. Cardiovascular Diseases
9.3.2.5. Neuroendocrine Diseases
9.3.2.6. Others
9.3.3. Others
9.4. Market Attractiveness, by Application
10. Global Multiplex Assays Market Analysis and Forecast, by End-user
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Biotechnology & Biopharmaceutical Companies
10.3.2. Academic & Research Centers
10.3.3. Diagnostic Centers
10.3.4. Hospitals
10.3.5. Others
10.4. Market Attractiveness, by End-user
11. Global Multiplex Assays Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Multiplex Assays Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Instruments & Software
12.2.2. Kits & Reagents
12.2.3. Services
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. Conventional PCR
12.4.2. Singleplex PCR
12.4.3. Multiplex PCR
12.4.4. Real-time PCR
12.4.5. Others
12.5. Market Attractiveness, by Technology
12.6. Market Value Forecast, By Type, 2017–2031
12.6.1. Protein
12.6.1.1. Planar
12.6.1.2. Bead-based
12.6.2. Nucleic Acid
12.6.2.1. Planar
12.6.2.2. Bead-based
12.6.3. Cell
12.7. Market Attractiveness, By Type
12.8. Market Value Forecast, by Application, 2017–2031
12.8.1. Companion Animal
12.8.2. Livestock Animal
12.9. Market Attractiveness, by Application
12.10. Market Value Forecast, by End-user, 2017–2031
12.10.1. Biotechnology & Biopharmaceutical Companies
12.10.2. Academic & Research Centers
12.10.3. Diagnostic Centers
12.10.4. Hospitals
12.10.5. Others
12.11. Market Attractiveness, by End-user
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Product
12.13.2. By Technology
12.13.3. By Type
12.13.4. By Application
12.13.5. By End-user
12.13.6. By Country
13. Europe Multiplex Assays Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Instruments
13.2.2. Consumables
13.2.2.1. Reagents & Kits
13.2.2.2. Micropipettes & Microplates
13.2.2.3. Others
13.2.3. Software
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. Multiplex RT-PCR
13.4.2. Flow Cytometry
13.4.3. Luminescence
13.4.4. Fluorescence
13.4.5. Others
13.5. Market Attractiveness, by Technology
13.6. Market Value Forecast, By Type, 2017–2031
13.6.1. Protein
13.6.1.1. Planar
13.6.1.2. Bead-based
13.6.2. Nucleic Acid
13.6.2.1. Planar
13.6.2.2. Bead-based
13.6.3. Cell
13.7. Market Attractiveness, By Type
13.8. Market Value Forecast, by Application, 2017–2031
13.8.1. Research & Development
13.8.1.1. Drug Discovery & Research
13.8.1.2. Biomarker Research & Application
13.8.2. Diagnosis
13.8.2.1. Infectious Diseases
13.8.2.2. Autoimmune Diseases
13.8.2.3. Cancer
13.8.2.4. Cardiovascular Diseases
13.8.2.5. Neuroendocrine Diseases
13.8.2.6. Others
13.8.3. Others
13.9. Market Attractiveness, by Application
13.10. Market Value Forecast, by End-user, 2017–2031
13.10.1. Biotechnology & Biopharmaceutical Companies
13.10.2. Academic & Research Centers
13.10.3. Diagnostic Centers
13.10.4. Hospitals
13.10.5. Others
13.11. Market Attractiveness, by End-user
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Product
13.13.2. By Technology
13.13.3. By Type
13.13.4. By Application
13.13.5. By End-user
13.13.6. By Country/Sub-region
14. Asia Pacific Multiplex Assays Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Instruments
14.2.2. Consumables
14.2.2.1. Reagents & Kits
14.2.2.2. Micropipettes & Microplates
14.2.2.3. Others
14.2.3. Software
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Technology, 2017–2031
14.4.1. Multiplex RT-PCR
14.4.2. Flow Cytometry
14.4.3. Luminescence
14.4.4. Fluorescence
14.4.5. Others
14.5. Market Attractiveness, by Technology
14.6. Market Value Forecast, By Type, 2017–2031
14.6.1. Protein
14.6.1.1. Planar
14.6.1.2. Bead-based
14.6.2. Nucleic Acid
14.6.2.1. Planar
14.6.2.2. Bead-based
14.6.3. Cell
14.7. Market Attractiveness, By Type
14.8. Market Value Forecast, by Application, 2017–2031
14.8.1. Research & Development
14.8.1.1. Drug Discovery & Research
14.8.1.2. Biomarker Research & Application
14.8.2. Diagnosis
14.8.2.1. Infectious Diseases
14.8.2.2. Autoimmune Diseases
14.8.2.3. Cancer
14.8.2.4. Cardiovascular Diseases
14.8.2.5. Neuroendocrine Diseases
14.8.2.6. Others
14.8.3. Others
14.9. Market Attractiveness, by Application
14.10. Market Value Forecast, by End-user, 2017–2031
14.10.1. Biotechnology & Biopharmaceutical Companies
14.10.2. Academic & Research Centers
14.10.3. Diagnostic Centers
14.10.4. Hospitals
14.10.5. Others
14.11. Market Attractiveness, by End-user
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Product
14.13.2. By Technology
14.13.3. By Type
14.13.4. By Application
14.13.5. By End-user
14.13.6. By Country/Sub-region
15. Latin America Multiplex Assays Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Instruments
15.2.2. Consumables
15.2.2.1. Reagents & Kits
15.2.2.2. Micropipettes & Microplates
15.2.2.3. Others
15.2.3. Software
15.3. Market Attractiveness, by Product
15.4. Market Value Forecast, by Technology, 2017–2031
15.4.1. Multiplex RT-PCR
15.4.2. Flow Cytometry
15.4.3. Luminescence
15.4.4. Fluorescence
15.4.5. Others
15.5. Market Attractiveness, by Technology
15.6. Market Value Forecast, By Type, 2017–2031
15.6.1. Protein
15.6.1.1. Planar
15.6.1.2. Bead-based
15.6.2. Nucleic Acid
15.6.2.1. Planar
15.6.2.2. Bead-based
15.6.3. Cell
15.7. Market Attractiveness, By Type
15.8. Market Value Forecast, by Application, 2017–2031
15.8.1. Research & Development
15.8.1.1. Drug Discovery & Research
15.8.1.2. Biomarker Research & Application
15.8.2. Diagnosis
15.8.2.1. Infectious Diseases
15.8.2.2. Autoimmune Diseases
15.8.2.3. Cancer
15.8.2.4. Cardiovascular Diseases
15.8.2.5. Neuroendocrine Diseases
15.8.2.6. Others
15.8.3. Others
15.9. Market Attractiveness, by Application
15.10. Market Value Forecast, by End-user, 2017–2031
15.10.1. Biotechnology & Biopharmaceutical Companies
15.10.2. Academic & Research Centers
15.10.3. Diagnostic Centers
15.10.4. Hospitals
15.10.5. Others
15.11. Market Attractiveness, by End-user
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Product
15.13.2. By Technology
15.13.3. By Type
15.13.4. By Application
15.13.5. By End-user
15.13.6. By Country/Sub-region
16. Middle East & Africa Multiplex Assays Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product, 2017–2031
16.2.1. Instruments
16.2.2. Consumables
16.2.2.1. Reagents & Kits
16.2.2.2. Micropipettes & Microplates
16.2.2.3. Others
16.2.3. Software
16.3. Market Attractiveness, by Product
16.4. Market Value Forecast, by Technology, 2017–2031
16.4.1. Multiplex RT-PCR
16.4.2. Flow Cytometry
16.4.3. Luminescence
16.4.4. Fluorescence
16.4.5. Others
16.5. Market Attractiveness, by Technology
16.6. Market Value Forecast, By Type, 2017–2031
16.6.1. Protein
16.6.1.1. Planar
16.6.1.2. Bead-based
16.6.2. Nucleic Acid
16.6.2.1. Planar
16.6.2.2. Bead-based
16.6.3. Cell
16.7. Market Attractiveness, By Type
16.8. Market Value Forecast, by Application, 2017–2031
16.8.1. Research & Development
16.8.1.1. Drug Discovery & Research
16.8.1.2. Biomarker Research & Application
16.8.2. Diagnosis
16.8.2.1. Infectious Diseases
16.8.2.2. Autoimmune Diseases
16.8.2.3. Cancer
16.8.2.4. Cardiovascular Diseases
16.8.2.5. Neuroendocrine Diseases
16.8.2.6. Others
16.8.3. Others
16.9. Market Attractiveness, by Application
16.10. Market Value Forecast, by End-user, 2017–2031
16.10.1. Biotechnology & Biopharmaceutical Companies
16.10.2. Academic & Research Centers
16.10.3. Diagnostic Centers
16.10.4. Hospitals
16.10.5. Others
16.11. Market Attractiveness, by End-user
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Product
16.13.2. By Technology
16.13.3. By Type
16.13.4. By Application
16.13.5. By End-user
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. DiaSorin S.p.A.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Thermo Fisher Scientific, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Seegene, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Meso Scale Diagnostics, LLC
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Abcam Limited
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. QIAGEN
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Bio-Rad Laboratories, Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Merck KGaA
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Quansys Biosciences
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Illumina, Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview